Onconova Therapeutics, Inc. filed its 10-K on Mar 30, 2023 for the period ending Dec 31, 2022. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.641 USD | -0.25% | -0.71% | -14.03% |
07/05 | Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy | CI |
04/04 | North American Morning Briefing : Focus Turns to -2- | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.03% | 13.52M | |
+33.63% | 50.93B | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+24.73% | 12.17B | |
+28.31% | 12.16B |
- Stock Market
- Equities
- TRAW Stock
- News Traws Pharma, Inc.
- Onconova Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt